Korro
IPOEditing RNA to rewrite the future of medicine
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- korrobio.com
- Total Funding
- $271.0M
- Last Round
- $85.0M Private EquityMar 2026
- Rounds
- 4
- Type
- Public
About
Korro Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing a new class of genetic medicines based on editing RNA. By leveraging endogenous RNA editing mechanisms, Korro's platform enables treatment of both rare and highly prevalent diseases. The company's lead program KRRO-110 targets alpha-1 antitrypsin deficiency (AATD). Founded in 2019 out of Atlas Venture, Korro merged with Frequency Therapeutics in 2023 and listed on Nasdaq (KRRO).
Tech & App Stack
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingSign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Mar 2026
Apr 2024
Jan 2022
Jan 2019
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
A development stage biotechnology company based in Seattle WA and San Diego CA that is establishi...
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
Clinical-stage biopharmaceutical company developing FcRn inhibitor therapies for IgG-mediated aut...
Commercial-stage oncology company pioneering antibody drug conjugate therapies for cancer treatment.
Biopharmaceutical oncology company focused on discovery, development, and commercialization of ca...
Global clinical-stage biopharmaceutical company pursuing novel drug development platforms for rar...